RxDoctor Payments Data

Loc Nguyen

Nurse Practitioner · Farmington, NHNPI 1801265731

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AstraZeneca at 39.2% of the total. Reporting peaked in 2022 at $2,257 and has fallen 74.4% since, to $577 in 2024. Among nurse practitioner clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,134in general payments, 2019–2025

Across 179 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$663
  • Lilly USA, LLC$500
  • Corcept Therapeutics$222
  • Bayer$194
  • Boehringer Ingelheim$162
  • plus $771 from 13 others

What the payments were for

  • Food & beverage$4,120100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,134 in reported general payments places this provider in the 95th percentile of 714 nurse practitioner providers in New Hampshire.

See all nurse practitioner providers in New Hampshire

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide52$66,279
OzempicSemaglutide26$28,730
JardianceEmpagliflozin31$24,750
KerendiaFinerenone22$21,437
MounjaroTirzepatide20$17,922
Synjardy XrEmpagliflozin/Metformin Hcl16$15,752
FarxigaDapagliflozin Propanediol16$11,835
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$1,694
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,325
Albuterol Sulfate HfaAlbuterol Sulfate22$770
Rosuvastatin Calcium20$769
Gabapentin21$736
Atorvastatin Calcium59$548
Levothyroxine Sodium46$535
Lisinopril56$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$500$84,20172 claims
Boehringer IngelheimJardiance, Synjardy Xr$162$40,50347 claims
Novo NordiskOzempic$663$28,73026 claims
BayerKerendia$194$21,43722 claims
AstraZenecaFarxiga$1,622$11,83516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 714 nurse practitioner providers in New Hampshire.

Other nurse practitioner in Farmington

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →